research Editorial Comment
5-ARI therapy may help prevent prostate cancer progression.
Search
for
Sort by
Research
150-180 / 1000+ resultsresearch US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
Urologists should screen for mental health issues before and during finasteride treatment.
research 054 Post Finasteride Syndrome: Guess Who-Demographics from FDA Database
Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.
research Post-Finasteride Syndrome (PFS) Update: Point/Counterpoint
Finasteride's link to health issues like male breast cancer, infertility, and prostate cancer needs more research through placebo-controlled trials to confirm.
research The impact of monotherapies for male androgenetic alopecia: A network meta‐analysis study
"Dutasteride 0.5 mg daily is the most effective treatment for male hair loss."
research Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice
Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
research Using 5 alpha reductase inhibitors safely: What primary care physicians need to know
5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
research FINASTERIDE IN MODERN MEDICINE: THERAPEUTIC APPLICATIONS AND SYSTEMIC HEALTH IMPLICATIONS
Finasteride is effective for hair loss and prostate issues but may cause lasting side effects.
research 5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond
5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
research BPH Medications May Increase Risk of Self-Harm, Depression
BPH medications may increase the risk of self-harm and depression, especially in the first 18 months.
research 5α- Reductase Inhibitors in Prostate Cancer: An Overview
5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.
research Signal Detection of Depression and Suicidality Associated with Finasteride and Dutasteride: Updated Pharmacovigilance Evidence and Recommendations for Comprehensive Psychiatric Assessment
Finasteride may cause depression and suicidal thoughts, especially in young men.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research BPH: costs and treatment outcomes.
Tamsulosin is a cost-effective treatment for BPH symptoms.
research Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome
The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.
research Novel Synthetic Steroid Derivatives: Target Prediction and Biological Evaluation of Antiandrogenic Activity
New steroid compounds may help with hormonal therapy and have potential benefits for glucose disorders, but more research is needed.
research Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: SYNERGY II study
Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.
research Low-dose finasteride in benign prostatic hyperplasia: a comprehensive narrative review of efficacy, safety, and preventative potential
Finasteride 1 mg may help prevent prostate issues, but more research is needed to confirm its benefits.
research Impact of Finasteride on Serum PSA Levels in Men With BPH: A Systematic Review
Finasteride lowers PSA levels and prostate size, requiring adjusted PSA interpretation for accurate cancer screening.
research Finasteride Use and Risk of Male Breast Cancer: A Case–Control Study Using Individual-Level Registry Data from Denmark, Finland, and Sweden
Finasteride use is not clearly linked to an increased risk of male breast cancer.
research Androgenetic Alopecia: An Evidence-Based Treatment Update
Effective treatments for male pattern baldness include oral finasteride and topical minoxidil, while topical minoxidil is best for female pattern baldness.
research Understanding patient and physician perceptions of male androgenetic alopecia treatments in Asia-Pacific and Latin America
Patients and doctors find current hair loss treatments unsatisfying and believe involving patients in decisions improves results.
research Finasteride in Frontal Fibrosing Alopecia: Joining the Dots!
Finasteride may help treat frontal fibrosing alopecia, but more research is needed.
research No increased risk of CV events with dutasteride vs finasteride
Dutasteride and finasteride have equal safety for treating BPH without increased heart risk.
research Treatment options for alopecia: an update, looking to the future
The document concludes that there are various treatments for different types of alopecia, but more research is needed for evidence-based treatments.
research Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date
Finasteride shows promise for female hair loss, but more research needed.
research Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis
Finasteride and dutasteride increase sexual dysfunction risk by 1.57 times in male hair loss treatment.
research Early-onset baldness and the risk of aggressive prostate cancer: findings from a case–control study
Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.
research Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases
Dutasteride and finasteride have similar effects on prostate cancer risk in BPH patients.